rebel Financial rebel Financial
← All Posts
AQST

Aquestive Therapeutics, Inc.

June 11, 2026 • Author: Phil Ratcliff • AQST
Item Proposal Vote
1 To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified
1.01 Gregory B. Brown, M.D. ✓ For
1.02 John S. Cochran ✓ For
1.03 Abigail L. Jenkins ✓ For
2 To approve, on a non-binding advisory basis, the compensation of our named executive officers. ✗ Against
3 To ratify the appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. ✓ For
4 The transaction of such other business as may properly come before the meeting. ✗ Against
Attachments
📄
AQST_Proxy_Statement.pdf 0.9 MB
📄
AQST_2024_Annual_Report.pdf 4.2 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.